AirInSpace owns a patented core technology, HEPA/MD™—the next generation of the Company’s initial Plasmer™ platform—that inactivates lethal airborne microorganisms. Developed initially for use in Russia’s MIR space station, the AirInSpace technology is in routine use today on the International Space Station (ISS). AirinSpace owns the exclusive rights to this oneof- a-kind technology, which shows up to 99.999% single-pass inactivation of airborne microorganisms. HEPA/MD technology is highly scalable and is being adapted by AirInSpace and its partners to a wide range of applications.

The Company’s first potential ‘homerun’ product in the U.S., based on HEPA/MD technology, is its FDA cleared PlasmairT2006 by AirInSpace mobile device that captures and inactivates biological particles from the air for medical purposes. Conventional HEPA (High Efficiency Particulate Air) filters are the nmost common airborne-decontamination method used in hospitals, but they do not inactivate the pathogens they trap and can therefore serve as a reservoir for incubating more pathogens that can release into the air to pose a lethal risk to patients, staff and maintenance personnel. Indeed, hospital-acquired (nosocomial) infections affect nearly one in 10 patients in developed countries. New regulations are being imposed to control airborne contamination levels, requiring hospitals to undertake massive renovations to upgrade their ventilation systems. Alternatively, hospitals are finding unprecedented success with deployment of PlasmairT2006 mobile units.

In addition to the hospital market ($1.8 billion opportunity), AirInSpace has developed applications for other markets, such as air transportation. On longer flights when cabin air is re-circulated for hours, concentrations of biocontaminants may rise to dangerous levels, and passengers are exposed to a higher risk of cross-infection. The onboard SARS transmission in 2003 is an alarming example. AirInSpace’s technology is now being installed in the main cabin ventilation systems of a major business jet manufacturer.

The Company believes its HEPA/MD technology is superior to all available and known air decontamination technologies. HEPA/MD technology offers critically unique advantages: (1) Microbe collection and inactivation; and (2) Physical efficiency (easy to get air through the system, no ‘clogging’, which means itis energy-friendly and less noisy). Nearly three dozen independent studies at prestigious academic labs such as Harvard School of Public Health (Boston) have tested HEPA/MD technology’s efficacy.